NO20052543L - 3-aminopyrrolidinderivater som modulatorer av kjemokinreseptorer. - Google Patents

3-aminopyrrolidinderivater som modulatorer av kjemokinreseptorer.

Info

Publication number
NO20052543L
NO20052543L NO20052543A NO20052543A NO20052543L NO 20052543 L NO20052543 L NO 20052543L NO 20052543 A NO20052543 A NO 20052543A NO 20052543 A NO20052543 A NO 20052543A NO 20052543 L NO20052543 L NO 20052543L
Authority
NO
Norway
Prior art keywords
modulators
chemokine receptors
chemokine
ccr2
useful
Prior art date
Application number
NO20052543A
Other languages
English (en)
Other versions
NO20052543D0 (no
NO330860B1 (no
Inventor
Chu-Biao Xue
Hao Feng
Brian Metcalf
Ganfeng Cao
Tuishing Huang
Chungsheng Zheng
Darius J Robinson
Amy Qi Han
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of NO20052543D0 publication Critical patent/NO20052543D0/no
Publication of NO20052543L publication Critical patent/NO20052543L/no
Publication of NO330860B1 publication Critical patent/NO330860B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
NO20052543A 2002-11-27 2005-05-26 3-aminopyrrolidinderivater, preparat omfattende slike forbindelser samt anvendelse av slike forbindelser for behandling av sykdom NO330860B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42960502P 2002-11-27 2002-11-27
US46397603P 2003-04-18 2003-04-18
PCT/US2003/037946 WO2004050024A2 (en) 2002-11-27 2003-11-26 3-aminopyrrolidine derivatives as modulators of chemokine receptors

Publications (3)

Publication Number Publication Date
NO20052543D0 NO20052543D0 (no) 2005-05-26
NO20052543L true NO20052543L (no) 2005-07-22
NO330860B1 NO330860B1 (no) 2011-08-01

Family

ID=32474514

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052543A NO330860B1 (no) 2002-11-27 2005-05-26 3-aminopyrrolidinderivater, preparat omfattende slike forbindelser samt anvendelse av slike forbindelser for behandling av sykdom

Country Status (27)

Country Link
US (4) US7834021B2 (no)
EP (2) EP2431357A3 (no)
JP (2) JP4828829B2 (no)
KR (1) KR100895968B1 (no)
CN (1) CN102153539B (no)
AT (1) ATE555087T1 (no)
AU (1) AU2003293129B2 (no)
BR (1) BRPI0316732B8 (no)
CA (1) CA2507501C (no)
CO (1) CO5690550A2 (no)
CR (2) CR7846A (no)
EA (1) EA010027B1 (no)
EC (1) ECSP055856A (no)
ES (1) ES2383296T3 (no)
GE (1) GEP20115290B (no)
HK (1) HK1079773A1 (no)
HU (1) HU230612B1 (no)
IL (1) IL168742A (no)
IS (1) IS2892B (no)
MX (1) MXPA05005660A (no)
NO (1) NO330860B1 (no)
NZ (1) NZ540290A (no)
PL (1) PL376925A1 (no)
RU (1) RU2355679C2 (no)
SE (1) SE529361C2 (no)
SG (1) SG173922A1 (no)
WO (1) WO2004050024A2 (no)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202133D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
AU2003293129B2 (en) * 2002-11-27 2009-03-12 Incyte Holdings Corporation 3-aminopyrrolidine derivatives as modulators of chemokine receptors
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
SE0302755D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel compounds
US20070021498A1 (en) * 2004-10-14 2007-01-25 Nafizal Hossain Novel tricyclic spiroderivatives as modulators of chemokine receptor activity
SE0303090D0 (sv) * 2003-11-20 2003-11-20 Astrazeneca Ab Novel compounds
KR100859027B1 (ko) * 2003-12-18 2008-09-17 인사이트 코포레이션 케모킨 수용체의 조절제로서의3-사이클로알킬아미노피롤리딘 유도체
SE0303541D0 (sv) 2003-12-22 2003-12-22 Astrazeneca Ab New compounds
AU2005234596B8 (en) * 2004-04-13 2011-06-16 Incyte Holdings Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
US7307086B2 (en) 2004-05-11 2007-12-11 Incyte Corporation 3-(4-heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors
CN1329374C (zh) * 2004-06-09 2007-08-01 上海靶点药物有限公司 作为ccr5拮抗剂的化合物
CN102382088A (zh) 2004-06-28 2012-03-21 因赛特公司 作为趋化因子受体调节剂的3-氨基环戊烷甲酰胺类
EP1763351B9 (en) 2004-06-28 2017-05-31 Incyte Holdings Corporation 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
GB0417801D0 (en) * 2004-08-10 2004-09-15 Novartis Ag Organic compounds
PA8653301A1 (es) * 2004-11-22 2006-11-09 Incyte Corp Incyte Corp Sales de la n-[2-({(3r)-1-[trans-4-hidroxi-4-(6-metoxipiridin-3-il) ciclohexil)pirrolidin
JP5118975B2 (ja) 2004-12-24 2013-01-16 アストラゼネカ・アクチエボラーグ Ｃｃｒ２ｂアンタゴニストとしてのヘテロ環式化合物
US8067415B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
GB0525957D0 (en) 2005-12-21 2006-02-01 Astrazeneca Ab Methods
CN101553493B (zh) * 2006-07-19 2012-07-04 阿斯利康(瑞典)有限公司 三环螺哌啶化合物、它们的合成和它们作为趋化因子受体活性调节剂的用途
TW200831497A (en) * 2006-10-12 2008-08-01 Epix Delaware Inc Carboxamide compounds and their use
MX2009005252A (es) 2006-11-17 2009-05-28 Abbott Lab Aminopirrolidinas como antagonistas del receptor de quimiocina.
WO2008063714A1 (en) * 2006-11-20 2008-05-29 N.V. Organon Metabolically-stabilized inhibitors of fatty acid amide hydrolase
ATE531945T1 (de) 2008-01-07 2011-11-15 Univ Vanderbilt Magnetventilanordnung
US7496166B1 (en) * 2008-04-29 2009-02-24 International Business Machines Corporation Dual clock spread for low clock emissions with recovery
EP2309857B1 (de) 2008-07-17 2013-07-03 Bayer CropScience AG Heterocyclische verbindungen als schädlingsbekämpfungsmittel
US20110230428A1 (en) * 2008-07-22 2011-09-22 John Wityak Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PE20110928A1 (es) * 2008-12-10 2012-01-05 Janssen Pharmaceutica Nv Derivados de 4-azetidinil-1-heteroaril-ciclohexanol como antagonistas de ccr2
KR101084551B1 (ko) * 2008-12-26 2011-11-17 양지화학 주식회사 Ｃｃｒ2 길항제로서의 3-아미노피롤리딘 유도체
EP2419417B1 (en) * 2009-04-16 2015-03-25 Janssen Pharmaceutica NV 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of ccr2
MX2011010964A (es) * 2009-04-17 2011-11-02 Janssen Pharmaceutica Nv Antagonistas del receptor 2 de citocina quimioatrayente de 4- azetidinil-1-fenil-ciclohexano.
MX2011010963A (es) * 2009-04-17 2011-11-02 Janssen Pharmaceutica Nv Antagonistas del receptor 2 de citocina quimiotrayente de ciclohexano unido al 4-azetidinil-1-heteroatomo.
KR101151415B1 (ko) 2009-07-10 2012-06-01 양지화학 주식회사 Ｃｃｒ２ 길항제로서의 피페라지닐에틸 3-아미노피롤리딘 유도체
TW201211027A (en) * 2010-06-09 2012-03-16 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of CCR2
CA2801934A1 (en) * 2010-06-17 2011-12-22 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of ccr2
KR101318656B1 (ko) 2010-10-08 2013-10-16 양지화학 주식회사 항천식 활성을 가진 3-아미노피롤리딘 유도체를 포함하는 약학 조성물
WO2012125661A1 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Substituted 3-azabicyclo[3.1.0]hexane derivatives useful as ccr2 antagonists
EP2751086A4 (en) 2011-08-30 2015-09-16 Chdi Foundation Inc KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHOD OF USE THEREOF
KR102181011B1 (ko) 2011-08-30 2020-11-20 씨에이치디아이 파운데이션, 인코포레이티드 키뉴레닌-3-모노옥시게나제 억제제, 약학적 조성물 및 이의 사용 방법
WO2013047813A1 (ja) 2011-09-30 2013-04-04 大鵬薬品工業株式会社 １，２，４－トリアジン－６－カルボキサミド誘導体
HUE033114T2 (en) 2011-11-18 2017-11-28 Heptares Therapeutics Ltd Muscarin M1 receptor agonists
WO2013149376A1 (en) * 2012-04-02 2013-10-10 Abbott Laboratories Chemokine receptor antagonists
EP3169684B1 (en) 2014-07-17 2019-06-26 CHDI Foundation, Inc. Combination of kmo inhibitor 6-(3-chloro-4-cyclopropoxyphenyl)pyrimidine-4-carboxylic acid with antiviral agent for treating hiv related neurological disorders
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
RU2606230C1 (ru) * 2015-10-20 2017-01-10 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (Z)-Этил 2-(4-(4-хлорфенил)-2,4-диоксо-3-(3-оксо-3,4-дигидрохиноксалин-2(1Н)-илиден)бутанамидо)-4-метил-5-фенилтиофен-3-карбоксилат, обладающий противодиабетической активностью, и способ его получения
CN109563085B (zh) 2016-07-28 2022-08-09 爱杜西亚药品有限公司 哌啶cxcr7受体调节剂
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
AU2018358160B2 (en) 2017-11-02 2023-03-16 Abbvie Inc. Modulators of the integrated stress pathway
EP3743422B1 (en) 2018-01-26 2024-03-13 Idorsia Pharmaceuticals Ltd Crystalline forms of the cxcr7 receptor antagonist (3s,4s)-1-cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
EP3947388A4 (en) 2019-04-02 2022-12-21 Aligos Therapeutics, Inc. LINKS DIRECTED AGAINST PRMT5
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
AR127055A1 (es) 2021-09-14 2023-12-13 Lilly Co Eli Sales agonistas de sstr4
WO2023081662A1 (en) * 2021-11-02 2023-05-11 Aria Pharmaceuticals, Inc. Bicyclic derivatives as ccr2 modulators
TW202334135A (zh) * 2021-11-02 2023-09-01 美商雅力雅製藥公司 化合物、組合物及方法
WO2023081665A1 (en) * 2021-11-02 2023-05-11 Aria Pharmaceuticals, Inc. Compounds as crr2 modulators
WO2023081661A1 (en) * 2021-11-02 2023-05-11 Aria Pharmaceuticals, Inc. Bicyclic derivatives as ccr2 modulators

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US26186A (en) * 1859-11-22 Cut-off arrangement for steam-valves
CH580582A5 (no) 1972-04-03 1976-10-15 Robins Co Inc A H
US4026836A (en) * 1975-12-29 1977-05-31 Texaco Development Corporation Isocyanurate foam catalyst
HU175454B (hu) * 1977-07-25 1980-08-28 Chinoin Gyogyszer Es Vegyeszet Sposob poluchenija novykh predel'nykh i chastichno predel'nykh n-acil-pirrol-2,5-dionov
US4333734A (en) * 1980-01-18 1982-06-08 Sloan-Kettering Institute For Cancer Research Diagnostic device for fecal occult blood and method of use
US4785119A (en) * 1985-10-11 1988-11-15 Tokyo Kasei Kogyo Co., Ltd. 3-aminopyrrolidine compound and process for preparation thereof
AU7665694A (en) * 1993-09-21 1995-04-10 Yamanouchi Pharmaceutical Co., Ltd. N-(3-pyrrolidinyl)benzamide derivative
US5770573A (en) 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
WO1997044329A1 (en) 1996-05-20 1997-11-27 Teijin Limited Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
AU729415B2 (en) 1996-07-12 2001-02-01 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
JP4166296B2 (ja) 1997-04-25 2008-10-15 塩野義製薬株式会社 ドーパミン受容体拮抗作用を有する化合物
CA2293408A1 (en) 1997-06-18 1998-12-23 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
WO1999025686A1 (en) * 1997-11-18 1999-05-27 Teijin Limited Cyclic amine derivatives and their use as drugs
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6197974B1 (en) 1998-10-26 2001-03-06 Abbott Laboratories Enantioselective synthesis of 3-aminopyrrolidines
CA2348879A1 (en) * 1998-11-02 2000-05-11 Welfide Corporation Pyrrolidine compound and pharmaceutical use thereof
US7217714B1 (en) 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
AU4796700A (en) 1999-05-13 2000-12-05 Dupont Pharmaceuticals Research Laboratories, Inc. Ureido-substituted cyclic amine derivatives and their use as drug
US7390830B1 (en) 1999-05-18 2008-06-24 Teijin Limited Remedies or prophylactics for diseases in association with chemokines
JP2003506364A (ja) * 1999-07-30 2003-02-18 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド システインプロテアーゼインヒビターとして有益な新規スクシネート誘導体化合物
CN1192773C (zh) 1999-08-04 2005-03-16 帝人株式会社 环胺ccr3拮抗剂
JP2001131145A (ja) 1999-08-20 2001-05-15 Toray Ind Inc 光学活性３−アミノピロリジン誘導体の製造法
DE60003702T2 (de) 1999-09-13 2004-04-22 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Heterocyclische verbindungen als reversible inhibitoren von cysteinproteasen
GB2355263A (en) * 1999-09-30 2001-04-18 Merck & Co Inc Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
CA2384240A1 (en) * 1999-10-15 2001-04-26 Dean A. Wacker Benzylcycloalkyl amines as modulators of chemokine receptor activity
DE60005401T2 (de) 1999-12-21 2004-05-06 Smithkline Beecham Corp. Carboxamidderivate von pyrrolidine und piperidine als urotensin-ii rezeptorantagonisten
US6362177B1 (en) * 2000-05-16 2002-03-26 Teijin Limited Cyclic amine derivatives and their use as drugs
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
US20020094989A1 (en) * 2000-10-11 2002-07-18 Hale Jeffrey J. Pyrrolidine modulators of CCR5 chemokine receptor activity
US7125887B2 (en) 2000-10-11 2006-10-24 Merck & Co., Inc. Pyrrolidine modulators of CCR5 chemokine receptor activity
US6670364B2 (en) * 2001-01-31 2003-12-30 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
US6538017B2 (en) 2001-03-09 2003-03-25 Ortho-Mcneil Pharmaceutical, Inc. Aminopyrrolidine sulfonamides as serine protease inhibitors
DE60322877D1 (de) 2002-04-29 2008-09-25 Merck Sharp & Dohme Tetrahydropyranylcyclopentyltetrahydroisochino-linmodulatoren der chemokinrezeptoraktivität
MY129850A (en) 2002-04-29 2007-05-31 Merck Sharp & Dohme Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
PT1501507E (pt) 2002-04-29 2008-08-12 Merck Sharp & Dohme Tetrahidropiranil ciclopentil tetrahidropiridopiridinas moduladoras da actividade dos receptores de quimioquinas
AU2003260072A1 (en) 2002-08-27 2004-03-19 Bristol-Myers Squibb Company Antagonists of chemokine receptors
JP2004083511A (ja) 2002-08-28 2004-03-18 Yamanouchi Pharmaceut Co Ltd アクリルアミド誘導体
RU2005111589A (ru) * 2002-09-17 2006-01-20 Актелион Фармасьютиклз Лтд. (Ch) Производные 1-пиридин-4-илмочевины
US7491737B2 (en) 2002-10-30 2009-02-17 Merck & Co., Inc. Heterarylpiperidine modulators of chemokine receptor activity
WO2004041161A2 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Tetrahydropyranyl cyclopentyl benzylamide modulators of chemokine receptor activity
EP1558576A4 (en) 2002-10-30 2008-04-16 Merck & Co Inc PIPERIDINYLCYCLOPENTYLARYLBENZYLAMIDE MODULATORS OF CHEMOKIN RECEPTORACTIVITY
JP2006514618A (ja) 2002-10-30 2006-05-11 メルク　エンド　カムパニー　インコーポレーテッド ケモカイン受容体活性のピペリジニル−アルファ−アミノアミドモジュレーター
US7247725B2 (en) 2002-10-30 2007-07-24 Merck & Co., Inc. Gamma-aminoamide modulators of chemokine receptor activity
AU2003293129B2 (en) * 2002-11-27 2009-03-12 Incyte Holdings Corporation 3-aminopyrrolidine derivatives as modulators of chemokine receptors
AR045875A1 (es) 2003-10-27 2005-11-16 Merck & Co Inc Procedimiento para la preparacion del antagonista ccr-2
BRPI0415836A (pt) 2003-10-27 2007-01-02 Merck & Co Inc composto, métodos para a modulação da atividade de receptor de quimocina em um mamìfero, e para o tratamento, a melhoria, o controle ou a redução do risco de uma doença ou distúrbio inflamatório e imunorregulatório, e de artrite reumatóide, composição farmacêutica
KR100859027B1 (ko) * 2003-12-18 2008-09-17 인사이트 코포레이션 케모킨 수용체의 조절제로서의3-사이클로알킬아미노피롤리딘 유도체
US20070117797A1 (en) 2004-01-02 2007-05-24 Goble Stephen D Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity
JP2007518799A (ja) 2004-01-20 2007-07-12 メルク　エンド　カムパニー　インコーポレーテッド ケモカイン受容体活性モジュレーターとしての２，６−二置換ピペリジン
CA2554387A1 (en) 2004-01-28 2005-08-11 Merck & Co., Inc. Aminocyclopentyl pyridopyrazinone modulators of chemokine receptor activity
AU2005234596B8 (en) * 2004-04-13 2011-06-16 Incyte Holdings Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
US7307086B2 (en) * 2004-05-11 2007-12-11 Incyte Corporation 3-(4-heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors
CN102382088A (zh) * 2004-06-28 2012-03-21 因赛特公司 作为趋化因子受体调节剂的3-氨基环戊烷甲酰胺类
EP1763351B9 (en) * 2004-06-28 2017-05-31 Incyte Holdings Corporation 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
PA8653301A1 (es) * 2004-11-22 2006-11-09 Incyte Corp Incyte Corp Sales de la n-[2-({(3r)-1-[trans-4-hidroxi-4-(6-metoxipiridin-3-il) ciclohexil)pirrolidin
TWI439452B (zh) 2005-05-13 2014-06-01 Otsuka Pharma Co Ltd 吡咯烷化合物（二）
MEP1008A (xx) * 2005-12-21 2010-02-10 Incyte Corp 3-aminociklopentankarboksamidi kao modulatori receptora hemokina

Also Published As

Publication number Publication date
SG173922A1 (en) 2011-09-29
JP2011251987A (ja) 2011-12-15
CN102153539B (zh) 2016-01-13
EP1565436B1 (en) 2012-04-25
JP2006516145A (ja) 2006-06-22
IS7905A (is) 2005-06-22
HUP0500848A3 (en) 2012-08-28
HU230612B1 (hu) 2017-04-28
IS2892B (is) 2014-09-15
WO2004050024A2 (en) 2004-06-17
EP2431357A3 (en) 2012-08-22
CN102153539A (zh) 2011-08-17
CA2507501C (en) 2011-10-04
SE529361C2 (sv) 2007-07-17
CR7846A (es) 2008-12-01
EP1565436A4 (en) 2007-07-18
US20060252751A1 (en) 2006-11-09
NO20052543D0 (no) 2005-05-26
BRPI0316732B1 (pt) 2018-03-13
GEP20115290B (en) 2011-09-26
AU2003293129B2 (en) 2009-03-12
KR20050087813A (ko) 2005-08-31
ATE555087T1 (de) 2012-05-15
US8362003B2 (en) 2013-01-29
BRPI0316732B8 (pt) 2021-05-25
US7985730B2 (en) 2011-07-26
KR100895968B1 (ko) 2009-05-07
RU2355679C2 (ru) 2009-05-20
BR0316732A (pt) 2005-10-18
NO330860B1 (no) 2011-08-01
US7834021B2 (en) 2010-11-16
EA010027B1 (ru) 2008-06-30
US20090247474A1 (en) 2009-10-01
US8729063B2 (en) 2014-05-20
CR20120152A (es) 2012-05-18
SE0501185L (sv) 2005-07-07
AU2003293129A1 (en) 2004-06-23
CO5690550A2 (es) 2006-10-31
EA200500875A1 (ru) 2005-12-29
WO2004050024A3 (en) 2004-07-29
IL168742A (en) 2010-06-16
US20110251168A1 (en) 2011-10-13
EP2431357A2 (en) 2012-03-21
ECSP055856A (es) 2006-03-01
HUP0500848A2 (en) 2007-08-28
NZ540290A (en) 2007-09-28
US20130116230A1 (en) 2013-05-09
PL376925A1 (pl) 2006-01-09
JP4828829B2 (ja) 2011-11-30
HK1079773A1 (en) 2006-04-13
MXPA05005660A (es) 2005-10-18
RU2005120020A (ru) 2006-01-20
CA2507501A1 (en) 2004-06-17
ES2383296T3 (es) 2012-06-20
EP1565436A2 (en) 2005-08-24

Similar Documents

Publication Publication Date Title
SE0501185L (sv) 3-aminopyrrolidinderivat som modulatorer av kemokinreceptorer
WO2005060665A3 (en) 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
DK1501507T3 (da) Tetrahydropyranyl-cyclopentyl-tertrahydropyridopyrindin-modulatorer af kemokin-receptor-aktivitet
BR0307833A (pt) Sìntese controlada de ziprasidona e suas composições
BRPI0508644A (pt) catalisador ácido sólido e método de utilizar o mesmo
ATE331715T1 (de) Thiazolylsubstituierte aminopyrimidine als pflanzenschutzmittel
GEP20084519B (en) 3-(4-heteroarylcyclo-hexylamino) cyclopenta-necarboxamides as modulators of chemokine receptors
CA2620129C (en) Diaminopyrimidines as p2x3 and p2x2/3 modulators
DE502005009201D1 (de) Substituierte 1-propinoyl-piperazine mit affinität für den mglur5 rezeptor zur behandlung von schmerzzuständen
ATE348097T1 (de) Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten
NO20055688L (no) Organiske forbindelser
MXPA03011722A (es) Derivados de piperidina utiles como moduladores de actividad de quimiocina.
ATE446753T1 (de) Verwendung von substituierten 2-thio-3,5-dicyano- 4-phenyl-6-aminopyridinen bei der behandlung von übelkeit und erbrechen
WO2004089366A8 (en) Bicyclic compounds as nr2b receptor antagonists
BRPI0519292A2 (pt) compostos orgÂnicos
SE0200919D0 (sv) Chemical compounds
EA200501593A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
PT1513824E (pt) Furanocarboxamidas
AU2003212769A1 (en) Piperidine derivatives useful as modulators of chemokine receptor activity
UA87449C2 (ru) Производные 3-аминопиролидина как модуляторы рецепторов хемокина
ATE521610T1 (de) Spiroverbindungen und -verfahren zur modulation von chemokin-rezeptor-aktivität
NO943765L (no) Aryloksybenzen-herbicidmidler
BRPI0507283A (pt) compostos orgánicos

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: INCYTE HOLDINGS CORPORATION, US

MK1K Patent expired